1.MMR trivalent vaccine based on safety, reactogenicity and immunogenicity observed in 12-24 month-old healthy Filipino children: Evaluation of lot-to-lot consistency of a live-attenuated measles-mumps-rubella
Salvacion Gatchalian ; Margaret Lu-Fong ; Leticia Cordero-Yap ; Jossie Rogacion ; Josefina Cadorna-Carlos ; Htay Htay Han ; Hans L Bock
Pediatric Infectious Disease Society of the Philippines Journal 2011;12(2):92-96
In this double-blind, randomized single-dose study, 194 healthy Filipino children aged 12-24 months were randomized into three groups (1:1:1) to receive one of the three lots of live-attenuated measles-mumps-rubella (MMR) vaccine to assess lot-to-lot consistency in safety and immunogenicity. Adverse events were recorded during 43-day post-vaccination follow-up period. Antibody levels were measured using ELISA pre-vaccination and on Day-60. No statistically significant differences were observed across groups for overall incidences of local and general symptoms (p>0.05) or immune response rates against the three antigens (p=0.835, 0.458 and 0.222 for anti-measles, anti-mumps and anti-rubella, respectively). The three lots demonstrated consistency in their reactogenicity and immunogenicity profile.
Human
;
Male
;
Female
;
Infant
;
MEASLES-MUMPS-RUBELLA VACCINE
;
ENZYME-LINKED IMMUNOSORBENT ASSAY